Sugi Predict

Sugi Predict / Compounds / SCHEMBL17801148

SCHEMBL17801148

SCHEMBL17801148

CCOC(=O)c1cc(C(=O)OCC)n(CC(=O)c2cnn(C)c2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.44
▸ JMJD6 Q6NYC1 3/20 0.38
▸ SMN1; SMN2 Q16637 5/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ POLB P06746 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ NPC1 O15118 3/20 0.36
▸ RAB9A P51151 3/20 0.36
▸ MAPT P10636 2/20 0.36
▸ FAAH O00519 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ JAK2 O60674 1/20 0.35
▸ JAK1 P23458 1/20 0.35
▸ JAK3 P52333 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19253483 0.89 RAB9A (0.39) LMNAJMJD6KMT2APOLBMEN1
SCHEMBL22449668 0.89 LMNA (0.40) LMNAJMJD6SMN1; SMN2TDP1KMT2A
SCHEMBL31131706 0.86 MET (0.36) LMNAJMJD6SMN1; SMN2NPC1RAB9A
SCHEMBL22549420 0.85 LMNA (0.38) LMNAJMJD6SMN1; SMN2TDP1KMT2A
SCHEMBL19300031 0.84 GRN (0.35) LMNAJMJD6KMT2APOLBMEN1
SCHEMBL28940409 0.79 GRN (0.37) LMNASMN1; SMN2MAPTKDM4E
SCHEMBL17801254 0.79 MAPT (0.50) LMNASMN1; SMN2TDP1MAPTGABRA2
SCHEMBL29977154 0.79 SMN1; SMN2 (0.46) LMNASMN1; SMN2TDP1KMT2APOLB
SCHEMBL28560572 0.79 SMN1; SMN2 (0.46) LMNASMN1; SMN2TDP1KMT2APOLB
SCHEMBL19253526 0.78 NPSR1 (0.39) LMNASMN1; SMN2KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709725-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF Progentos Therapeutics, Inc. (US) 2026-03-18 — — EP disclosed
US-20250034150-A1 BTK INHIBITORS BIOGEN MA INC. 2025-01-30 — — US disclosed
WO-2024233642-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PROGENTOS THERAPEUTICS, INC. (US) 2024-11-14 — — WO disclosed
US-12129256-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives PFIZER INC. (US) 2024-10-29 — — US disclosed
CN-118804915-A BTK inhibitors 渤健马萨诸塞州股份有限公司 2024-10-18 — — CN disclosed
EP-4429770-A1 BTK INHIBITORS Biogen MA Inc. (US) 2024-09-18 — — EP disclosed
CN-113924301-B Pyrazolopyrazine derivative compound, pharmaceutical composition and application thereof 北京普祺医药科技股份有限公司 2024-08-16 — — CN disclosed
US-20240083900-A1 PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS BIOGEN MA INC. (US) 2024-03-14 — — US disclosed
US-11851434-B2 Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-12-26 — — US disclosed
EP-4244223-A1 PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS Biogen MA Inc. (US) 2023-09-20 — — EP disclosed
US-10144738-B2 Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives PFIZER INC. (US) 2018-12-04 — — US disclosed
WO-2018136661-A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS ANDREWS STEVEN W (US) 2018-07-26 — — WO disclosed
US-20170362240-A1 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2017-12-21 — — US disclosed
EP-3227297-A1 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS Array Biopharma, Inc. (US) 2017-10-11 — — EP disclosed
WO-2017144995-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS PFIZER INC. (US) 2017-08-31 — — WO disclosed
WO-2017144995-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS PFIZER INC. (US) 2017-08-31 — — WO disclosed
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2017-08-24 — — US disclosed
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2017-08-24 — — US disclosed
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES PFIZER INC. (US) 2017-08-24 — — US disclosed
WO-2016090285-A1 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2016-06-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12129256-B2 Pyrazolo[1,5-a]pyrazin-4-yl derivatives CBR3, CNR1, CBR1 LMNA 3633/4885JMJD6 2158/4885SMN1; SMN2 3614/4885
US-20170362240-A1 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS JAK1, JAK3, JAK2 LMNA 4865/4885JMJD6 463/4885SMN1; SMN2 4032/4885
US-11851434-B2 Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors RET, BRAF, ROR1 LMNA 2693/4885JMJD6 1961/4885SMN1; SMN2 1094/4885
US-20240083900-A1 PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS BTK, SYK, LYN LMNA 4722/4885JMJD6 2933/4885SMN1; SMN2 4688/4885
US-10144738-B2 Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives JAK1, JAK2, JAK3 LMNA 3403/4885JMJD6 1041/4885SMN1; SMN2 4532/4885
US-20170240552-A1 PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES CBR3, CNR1, CCR6 LMNA 3565/4885JMJD6 2023/4885SMN1; SMN2 3561/4885
US-20250034150-A1 BTK INHIBITORS BTK, SYK, LYN LMNA 4618/4885JMJD6 2393/4885SMN1; SMN2 4482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.